Ironwood Pharmaceuticals, Inc.

$3.92+6.81%(+$0.25)
TickerSpark Score
81/100
Strong
100
Valuation
80
Profitability
55
Growth
68
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRWD research report →

52-Week Range64% of range
Low $0.55
Current $3.92
High $5.78

Companywww.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

CEO
Thomas A. McCourt
IPO
2010
Employees
253
HQ
Boston, MA, US

Price Chart

+500.86% · this period
$5.39$2.98$0.57May 20Nov 18May 20

Valuation

Market Cap
$645.28M
P/E
6.27
P/S
1.78
P/B
-2.95
EV/EBITDA
4.97
Div Yield
0.00%

Profitability

Gross Margin
99.62%
Op Margin
55.83%
Net Margin
28.26%
ROE
-38.88%
ROIC
29.97%

Growth & Income

Revenue
$296.15M · -15.72%
Net Income
$24.02M · 2629.20%
EPS
$0.15 · 2627.27%
Op Income
$118.76M
FCF YoY
22.83%

Performance & Tape

52W High
$5.78
52W Low
$0.55
50D MA
$3.78
200D MA
$3.00
Beta
0.30
Avg Volume
2.83M

Get TickerSpark's AI analysis on IRWD

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 17, 26DENNER ALEXANDER Jsell6,725,000
Mar 17, 26DENNER ALEXANDER Jsell5,800
Mar 13, 26DENNER ALEXANDER Jother4,451
Mar 10, 26John Minardoother136,612
Mar 10, 26Martini Gregory S.other136,612
Mar 10, 26Gaskins Tammi Lother136,612
Mar 10, 26Shetzline Michaelother136,612
Mar 10, 26Silver Ronaldother163,934
Mar 10, 26MCCOURT Thomas Aother409,836
Feb 23, 26John Minardosell17,439

Our IRWD Coverage

We haven't published any research on IRWD yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate IRWD Report →

Similar Companies